Healthy volunteers test new Drug's safety in Early-Stage trial
NCT ID NCT06797375
First seen Nov 18, 2025 · Last updated May 13, 2026 · Updated 21 times
Summary
This early-stage study tested the safety and how the body handles a new drug called RLYB116 in 16 healthy adults aged 18 to 55. Participants received multiple doses, and researchers monitored side effects, drug levels, and immune reactions. The goal was to gather safety information, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network Brisbane
Brisbane, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.